Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Tan WS, Rodney S, Lamb B, et al. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31.
   PubMed Web of Science ®Google Scholar
• Scarpato KR, Morgans AK, Moses KA. Optimal management of muscle-invasive bladder cancer – a review. Res Rep Urol. 2015;7:143.
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology. Bladder cancer, version 2.2016 ed; 2016. [cited 2016 Dec 21]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf
   Google Scholar
• Cheetham PJ, Petrylak DP. New agents for the treatment of advanced bladder cancer. Oncology (Williston Park). 2016;30:571.
   PubMed Web of Science ®Google Scholar
• Oing C, Rink M, Oechsle K, et al. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond – a comprehensive review of the current literature. J Urol. 2016;195:254–263.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang SD, McCrudden C, et al. The prognostic significance of PD-L1 in bladder cancer. Oncol Rep. 2015;33:3075.
   PubMed Web of Science ®Google Scholar
• Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580–6587.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
   PubMed Web of Science ®Google Scholar
• Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56:1173.
   PubMed Web of Science ®Google Scholar
• Montironi R, Santoni M, Tartari F, et al. Testing PD-1/PD-L1 expression in cancer therapy: pathologic insights and economic sustainability. Arch Pathol Lab Med. 2016;140:501–502.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
   PubMed Web of Science ®Google Scholar
• A study of nivolumab in participants with metastatic or unresectable bladder cancer. ClinicalTrials.gov, NCT02387996. [cited 2016 Dec 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02387996
   Google Scholar
• A study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475-045/KEYNOTE-045). ClinicalTrials.gov, NCT02256436. [cited 2016 Nov 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02256436
   Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Keynote-045: open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. 2016 SITC Annual Meeting; 2016 Nov 9–13; National Harbor, MD.
   Google Scholar
• Galsky MD, Retz M, Siefker-Radtke AO, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: results from the phase II CheckMate-275 study. 2016 ESMO Congress; 2016 Oct 7–11; Copenhagen, Denmark.
   Google Scholar
• First-line gemcitabine, cisplatin + ipilimumab for metastatic urothelial carcinoma. ClinicalTrials.gov, NCT01524991. [cited 2016 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01524991
   Google Scholar
• Genenteq: tecentriq prescribing information. 2016. [cited 2016 Oct]. Available from: http://www.gene.com/download/pdf/tecentriq_prescribing.pdf
   Google Scholar
• Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8:593.
   PubMed Web of Science ®Google Scholar
• Wafula PO, Teles A, Schumacher A, et al. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol. 2009;62:283–292.
   PubMed Web of Science ®Google Scholar
• Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202:231–237.
   PubMed Web of Science ®Google Scholar
• Tecentriq(R) [package insert]. Vol. 2016. South San Francisco (CA): Genentech, Inc.; 2016.
   Google Scholar
• Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40:121–127.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562.
   PubMed Web of Science ®Google Scholar
• Mizugaki H, Yamamoto N, Murakami H, et al. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34:596–603.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180.
   PubMed Web of Science ®Google Scholar
• McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res. 2007;13:716s–720s.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29:2432–2438.
   PubMed Web of Science ®Google Scholar
• Han KS, Joung JY, Kim TS, et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer. 2008;98:86.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–4461.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Bellmunt J, Maughan BL, et al. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014;12:130–137.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016 Dec 7. pii: S0140-6736(16)32455-2.
   Web of Science ®Google Scholar
• Rexer H, Retz M, Albers P. [Adjuvant study of high-risk muscle invasive urothelial carcinoma: open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010) – study AB 53/15 of the AUO]. Urologe A. 2016;55:1491.
   PubMedGoogle Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:e0130142.
   PubMed Web of Science ®Google Scholar